NASDAQ:AKUS

Akouos Stock Forecast, Price & News

$13.00
-0.46 (-3.42 %)
(As of 06/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$12.86
$13.38
50-Day Range
$11.87
$15.96
52-Week Range
$11.64
$30.67
Volume95,126 shs
Average Volume181,365 shs
Market Capitalization$447.84 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AKUS News and Ratings via Email

Sign-up to receive the latest news and ratings for Akouos and its competitors with MarketBeat's FREE daily newsletter.


Akouos logo

About Akouos

Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. Akouos, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.57 out of 5 stars

Medical Sector

478th out of 2,096 stocks

Pharmaceutical Preparations Industry

233rd out of 830 stocks

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Akouos (NASDAQ:AKUS) Frequently Asked Questions

Is Akouos a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akouos in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Akouos stock.
View analyst ratings for Akouos
or view top-rated stocks.

What stocks does MarketBeat like better than Akouos?

Wall Street analysts have given Akouos a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Akouos wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Akouos' next earnings date?

Akouos is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Akouos
.

How were Akouos' earnings last quarter?

Akouos, Inc. (NASDAQ:AKUS) issued its quarterly earnings results on Wednesday, May, 12th. The company reported ($0.47) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.38) by $0.09.
View Akouos' earnings history
.

What price target have analysts set for AKUS?

5 brokerages have issued 12-month price targets for Akouos' stock. Their forecasts range from $20.00 to $40.00. On average, they expect Akouos' stock price to reach $30.00 in the next twelve months. This suggests a possible upside of 130.8% from the stock's current price.
View analysts' price targets for Akouos
or view top-rated stocks among Wall Street analysts.

Who are Akouos' key executives?

Akouos' management team includes the following people:
  • Dr. Emmanuel Simons M.B.A., Ph.D., Co- Founder, Pres, CEO & Director (Age 38, Pay $495.77k)
  • Dr. Michael John McKenna M.D., Co-Founder, Chief Medical Officer & Member of Scientific Advisory Board (Age 64, Pay $445.08k)
  • Dr. Gregory Scott Robinson, Chief Scientific Officer (Age 62, Pay $428.02k)
  • Dr. Luk H. Vandenberghe M.D., Ph.D., Founder & Member of Scientific Advisory Board
  • Mr. William F. Sewell Ph.D., Founder & Member of Scientific Advisory Board
  • Mr. Richard Smith M.D., Founder & Member of Scientific Advisory Board
  • Ms. Sachiyo Minegishi, CFO, Treasurer, Assistant Sec. & Principal Accounting Officer (Age 43)
  • Ms. Jennifer Anne Wellman, Chief Operating Officer (Age 43)
  • Dr. Alan K. Smith, Chief Technology Officer (Age 63)
  • Dr. Karoline K. Shair, Sr. VP, Gen. Counsel, Chief Legal Officer & Corp. Sec.

Who are some of Akouos' key competitors?

What other stocks do shareholders of Akouos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akouos investors own include NVIDIA (NVDA), Honeywell International (HON), QUALCOMM (QCOM), Raytheon Technologies (RTX), CVS Health (CVS), Johnson & Johnson (JNJ), Cisco Systems (CSCO), The Home Depot (HD), Pfizer (PFE) and The Procter & Gamble (PG).

When did Akouos IPO?

(AKUS) raised $124 million in an initial public offering on Friday, June 26th 2020. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler acted as the underwriters for the IPO and BTIG was co-manager.

What is Akouos' stock symbol?

Akouos trades on the NASDAQ under the ticker symbol "AKUS."

Who are Akouos' major shareholders?

Akouos' stock is owned by many different institutional and retail investors. Top institutional investors include Federated Hermes Inc. (7.29%), BlackRock Inc. (5.80%), Citadel Advisors LLC (3.92%), Geode Capital Management LLC (1.01%), Northern Trust Corp (0.68%) and Caas Capital Management LP (0.67%).

Which institutional investors are selling Akouos stock?

AKUS stock was sold by a variety of institutional investors in the last quarter, including Caas Capital Management LP, Millennium Management LLC, Morgan Stanley, Citadel Advisors LLC, Victory Capital Management Inc., Citigroup Inc., and Ensign Peak Advisors Inc.

Which institutional investors are buying Akouos stock?

AKUS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Federated Hermes Inc., JPMorgan Chase & Co., Geode Capital Management LLC, Mercer Global Advisors Inc. ADV, Envestnet Asset Management Inc., Northern Trust Corp, and Nuveen Asset Management LLC.

How do I buy shares of Akouos?

Shares of AKUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Akouos' stock price today?

One share of AKUS stock can currently be purchased for approximately $13.00.

How much money does Akouos make?

Akouos has a market capitalization of $447.84 million. The company earns $-48,600,000.00 in net income (profit) each year or ($2.77) on an earnings per share basis.

How many employees does Akouos have?

Akouos employs 69 workers across the globe.

What is Akouos' official website?

The official website for Akouos is www.akouos.com.

Where are Akouos' headquarters?

Akouos is headquartered at 645 SUMMER STREET SUITE 200, BOSTON MA, 02210.

How can I contact Akouos?

Akouos' mailing address is 645 SUMMER STREET SUITE 200, BOSTON MA, 02210. The company can be reached via phone at 857-410-1818 or via email at [email protected]


This page was last updated on 6/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.